206 related articles for article (PubMed ID: 15711734)
41. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
42. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Rømer J; Pyke C; Lund LR; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
Int J Cancer; 1994 May; 57(4):553-60. PubMed ID: 8181859
[TBL] [Abstract][Full Text] [Related]
43. The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.
Engelholm LH; Nielsen BS; Danø K; Behrendt N
Trends Cardiovasc Med; 2001 Jan; 11(1):7-13. PubMed ID: 11413046
[TBL] [Abstract][Full Text] [Related]
44. Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Krstic J; Maslovaric I; Santibanez JF
Recent Pat Anticancer Drug Discov; 2014; 9(3):354-71. PubMed ID: 24827562
[TBL] [Abstract][Full Text] [Related]
45. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
Testa JE; Quigley JP
Cancer Metastasis Rev; 1990 Dec; 9(4):353-67. PubMed ID: 2129023
[TBL] [Abstract][Full Text] [Related]
46. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?
Blasi F
Immunol Today; 1997 Sep; 18(9):415-7. PubMed ID: 9293155
[No Abstract] [Full Text] [Related]
47. Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Rantala J; Kemppainen S; Ndode-Ekane XE; Lahtinen L; Bolkvadze T; Gurevicius K; Tanila H; Pitkänen A
Epilepsy Behav; 2015 Jan; 42():117-28. PubMed ID: 25506794
[TBL] [Abstract][Full Text] [Related]
48. Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Mohanam S; Sawaya RE; Yamamoto M; Bruner JM; Nicholson GL; Rao JS
J Neurooncol; 1994; 22(2):153-60. PubMed ID: 7745467
[TBL] [Abstract][Full Text] [Related]
49. Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes.
Diaz A; Merino P; Manrique LG; Cheng L; Yepes M
J Cereb Blood Flow Metab; 2019 Nov; 39(11):2157-2171. PubMed ID: 29890880
[TBL] [Abstract][Full Text] [Related]
50. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.
Nusrat AR; Chapman HA
J Clin Invest; 1991 Mar; 87(3):1091-7. PubMed ID: 1847936
[TBL] [Abstract][Full Text] [Related]
51. The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function.
Preissner KT; Kanse SM; Chavakis T; May AE
Basic Res Cardiol; 1999 Oct; 94(5):315-21. PubMed ID: 10543306
[TBL] [Abstract][Full Text] [Related]
52. The urokinase receptor as an entertainer of signal transduction.
D'Alessio S; Blasi F
Front Biosci (Landmark Ed); 2009 Jan; 14(12):4575-87. PubMed ID: 19273372
[TBL] [Abstract][Full Text] [Related]
53. Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Kaczmarek JZ; Skottrup PD
Mol Immunol; 2015 Jun; 65(2):384-90. PubMed ID: 25749705
[TBL] [Abstract][Full Text] [Related]
54. Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer.
Conforti G; Dominguez-Jimenez C; Rønne E; Høyer-Hansen G; Dejana E
Blood; 1994 Feb; 83(4):994-1005. PubMed ID: 8111067
[TBL] [Abstract][Full Text] [Related]
55. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule.
Dear AE; Medcalf RL
Eur J Biochem; 1998 Mar; 252(2):185-93. PubMed ID: 9523687
[TBL] [Abstract][Full Text] [Related]
56. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Gonias SL; Hembrough TA; Sankovic M
Front Biosci; 2001 Nov; 6():D1403-11. PubMed ID: 11689350
[TBL] [Abstract][Full Text] [Related]
57. Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1.
Kunigal S; Kusch A; Tkachuk N; Tkachuk S; Jerke U; Haller H; Dumler I
Blood; 2003 Dec; 102(13):4377-83. PubMed ID: 12920039
[TBL] [Abstract][Full Text] [Related]
58. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.
Alfano D; Franco P; Stoppelli MP
Front Cell Dev Biol; 2022; 10():818616. PubMed ID: 35493073
[TBL] [Abstract][Full Text] [Related]
59. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.
Ossowski L
J Cell Biol; 1988 Dec; 107(6 Pt 1):2437-45. PubMed ID: 2848851
[TBL] [Abstract][Full Text] [Related]
60. Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes.
Del Rosso M; Fibbi G; Dini G; Grappone C; Pucci M; Caldini R; Magnelli L; Fimiani M; Lotti T; Panconesi E
J Invest Dermatol; 1990 Mar; 94(3):310-6. PubMed ID: 2155272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
